AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02591147 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Group 2 (Placebo)
Description: Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
Study NCT03907878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Liquid in vial
Study NCT03933215 — intervention group
Intervention type: DRUG
Intervention: Cladribine Tablets
Description: No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Study NCT00616512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GF Strong Water Protocol
Description: The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
Study NCT03905616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging
Description: In a 2-hour session, the subject we be shown different control and experimental conditions (all being visual stimuli) in perceptive tasks.
Study NCT04554446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-MSAT(Motion style acupuncture treatment using traction)
Description: Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
Study NCT00768300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
Study NCT00768300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ambrisentan was administered orally once daily.
Study NCT00841087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
Study NCT00841087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injection subcutaneously at bedtime
Study NCT00841087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injection subcutaneously immediately before each meal.
Study NCT00841087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injection subcutaneously immediately before each meal.
Study NCT04002596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Neuro Thalamotomy Treatment
Description: Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
Study NCT05348161 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Samples including blood and tissue collection
Description: Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
Study NCT05348161 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CTC detection
Description: Peripheral blood collected from patients will be administrated to CTC detection.
Study NCT05348161 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ctDNA detection
Description: DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
Study NCT05348161 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 10×genomics single cell RNA sequence
Description: Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
Study NCT05348161 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whole exon sequence
Description: DNA will be extracted from patients' tissue and administrated to whole exon sequence.
Study NCT05348161 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Proteomics detection
Description: Peripheral blood collected from patients will be administrated to proximity extension assay .
Study NCT03106155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vistusertib (AZD2014)
Description: vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
Study NCT01761838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMT for low back pain patients
Description: High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
Study NCT01761838 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pain induction (optional)
Description: A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
Study NCT01761838 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low back pain participants without SMT
Description: No treatment
Study NCT02913079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-stand desk
Study NCT02913079 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sitting desk
Study NCT00495833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized brochure
Description: either photo personalization, blood pressure personalization, both, or no personalization
Study NCT00495833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotional gift
Description: half of participants who go to a fire station will receive a gift card.
Study NCT01897012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT01442792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFH
Description: Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
Study NCT01442792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 10 mg single dose Rivaroxaban (per os)
Study NCT01442792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 20 mg single dose Rivaroxaban (per os)
Study NCT01442792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939) and UFH
Description: 10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
Study NCT03693339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
Study NCT04866875 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dieting
Description: The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
Study NCT04866875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dieting
Description: The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
Study NCT01762254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incisionless laparoscopic colectomy
Description: Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
Study NCT01762254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic colectomy
Description: Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
Study NCT04872998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Count Reduction
Description: Subjects reduce daily step counts by approximately 70% through monitoring and recording from step-count monitor
Study NCT02236416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
Study NCT02236416 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
Study NCT02080260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Single agent drug therapy with regorafenib
Study NCT00596583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DYME
Description: 2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
Study NCT00596583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DYME
Description: 2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
Study NCT03353103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride F-18 PET imaging
Description: prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
Study NCT03031392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sensitivity test
Description: Routine clinical and radiographic examination
Study NCT01032317 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency Catheter Ablation
Description: The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
Study NCT04921085 — intervention group
Intervention type: OTHER
Intervention: Cross-sectional obeservational survey
Description: Cross-sectional obeservational survey
Study NCT00798317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 125µg
Description: 125µg of ocriplasmin intravitreal injection
Study NCT00798317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravitreal injection placebo.
Study NCT01278589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plantago asiatica L. extract 5g
Description: Liquid (80g) containing Plantago asiatica L. extract 5g
Study NCT01278589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plantago asiatica L. extract 10g
Description: Liquid (80g) containing Plantago asiatica L. extract 10g
Study NCT01278589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plantago asiatica L. extract 20g
Description: Liquid (80g) containing Plantago asiatica L. extract 20g
Study NCT01278589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid (80g) without Plantago asiatica L. extract
Study NCT01930890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB023
Study NCT01930890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: titrated to a target daily dose of 2 g (1 g twice daily)
Study NCT01930890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral corticosteroids
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
Study NCT01095354 — intervention group
Intervention type: DRUG
Intervention: Sodium Chloride Inhalation
Description: Spirometry: all subjects Plethysmography and exhaled nitric oxide: >6 years Multiple Breath Washout: Tidal breathing using a facemask \<9 years or mouthpiece >9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches \<0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects >10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum.
Study NCT02239146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
Study NCT02239146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
Study NCT02582281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine device TCu 380A
Study NCT02476929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic nose
Description: To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
Study NCT03338166 — intervention group
Intervention type: OTHER
Intervention: LDH serum level
Description: Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
Study NCT01897012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04570683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab 10 MG/ML
Description: Se previously
Study NCT04570683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablative fractionated laser
Description: Se previously
Study NCT04944732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory examination, auxiliary examination, pathological results
Description: Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)
Study NCT01066351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta erythropoietin
Description: The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
Study NCT01066351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
Study NCT03234296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Intravenous antibiotic followed by per oral antibiotics
Study NCT04554446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Korean medicine treatment
Description: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
Study NCT04554446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Korean medicine treatment
Description: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
Study NCT03234296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo followed by per oral placebo
Study NCT01897012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study NCT04380259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)
Description: MBTR-R is a mindfulness-based group intervention of nine 2.5-hour weekly sessions. MBTR-R format and structure parallel MBSR (mindfulness-based stress reduction) and MBCT (mindfulness-based cognitive therapy). MBTR-R includes systematic training in formal and informal mindfulness practices with trauma-sensitive adaptations and home practice. Trauma-sensitive adaptations include a safe place practice, psychoeducation about posttraumatic stress, stress reactivity, as well as self-compassion practices to cope with fear, self-judgement, guilt and shame. Socio-cultural adaptations include real-time linguistic translation of each session by a cultural mediator from the refugee community and use of socio-culturally specific metaphors. MBTR-R groups were conducted for men and women separately and delivered in an accessible, safe space in the local refugee community. Group meetings included a shared meal of traditional Eritrean food and female participants were offered free child care.
Study NCT00198510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Description: 55 IU of Vitrase
Study NCT00198510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Description: 75 IU of Vitrase
Study NCT00218283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenge
Description: Oral Nicotine replacement product
Study NCT00218283 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Counseling
Description: Use of behavioral counseling to reduce tobacco use.
Study NCT03070054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20ml 0.25% bupivacaine-epinephrine
Description: Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
Study NCT04524455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be administered as a continuous intravenous infusion (cIV).
Study NCT04524455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be administered as an intravenous infusion (IV).
Study NCT04524455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Premedication
Description: Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
Study NCT01013415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Study NCT01013415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cells
Study NCT01675128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 183750
Study NCT04118790 — intervention group
Intervention type: OTHER
Intervention: Clinical Assessment
Description: 1. Medical history and details of the vascular incident will be collected from the patient and the medical journal. (Duration: 1hr)~2. Neuropsychological measures collected using test measures and questionaries (duration approx 45-60 min).
Study NCT04118790 — intervention group
Intervention type: PROCEDURE
Intervention: MRI scan
Description: 1. MRI scan session, which includes Structural, Quantitative, Functional and Diffusion MRI sequences. (maximum duration: 90 min).
Study NCT01660100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein antrum isolation (PVAI)
Description: In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.